Clinical trials: Oral Candidiasis
Vulvovaginal Candidiasis
Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis
This is a randomized, multicenter, evaluator blinded study to evaluate the safety, tolerability, efficacy and pharmacokinetics of SCY-078 compared to Fluconazole in adult patients with moderate to severe Vulvovaginal Candidiasis…
- Trial name
- NCT02679456
- Testing
- SCY-078, Fluconazole
- Where
- 2 sites in Dominican Republic
- Volunteers
- 96 people
- Sponsor
- Scynexis, Inc.
Candidiasis, Oral
Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis
Phase 1 Single Centre, open-labeled Clinical Trial to Evaluate the Safety and Tolerability of Topical Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis.
- Trial name
- NCT06120816
- Testing
- Nitric Oxide
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Sanotize Research and Development corp.
Candidemia, Mycoses
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by optional oral fluconazole).
- Conditions
- Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
- Trial name
- ReSTORE (NCT03667690)
- Testing
- Rezafungin for Injection, Caspofungin, Fluconazole
- Where
- 132 sites in United States, Argentina and 16 more
- Volunteers
- 199 people
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Candidiasis, Oral
Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis
The objectives of this study are to compare the efficacy and safety of Roxane's clotrimazole troches vs. Mycelex troches in HIV positive patients with oropharyngeal candidiasis, where this condition has been diagnosed by clinical…
- Trial name
- NCT02184351
- Testing
- Roxanes's clotrimazole troches, Mycelex® troches
- Volunteers
- 187 people
- Sponsor
- Boehringer Ingelheim
Candidiasis, Oral, HIV Infections
Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome
To compare the efficacy, safety, and toleration of fluconazole as a single daily oral suspension for 14 days versus nystatin oral suspension 4 times daily for 14 days in the treatment of oropharyngeal candidiasis in patients with…
- Trial name
- NCT00002112
- Testing
- Nystatin, Fluconazole
- Where
- 5 sites in United States
- Sponsor
- Pfizer
Oral Candidiasis
Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis
The purpose of this study is to determine the optimal dose of PAC113 mouthrinse for treatment of oral candidiasis in HIV seropositive patients.
- Trial name
- NCT00659971
- Testing
- PAC113
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- Pacgen Biopharmaceuticals Corporation
Candidiasis, Vulvovaginal
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
The purpose of this study is to determine if the novel oral agent VT-1161 is safe and effective in treating patients with acute vulvovaginal candidiasis (also referred to as yeast infection).
- Trial name
- NCT01891331
- Testing
- VT-1161, Fluconazole
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Viamet
Candida Vulvovaginitis
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)
This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in female subjects 12 years and older with AVVC.
- Trial name
- NCT03734991
- Testing
- Ibrexafungerp
- Where
- 25 sites in United States
- Volunteers
- 376 people
- Sponsor
- Scynexis, Inc.
Candidiasis Vulvaginitis
Efficacy Vulvovaginitis Candida
To compare the therapeutic efficacy of 10 mg, 40 mg, 80 mg, 160 mg and 320 mg of albaconazole, as a single oral dose, in women affected by acute non-complicated vulvovaginitis due to Candida spp.
- Trial name
- NCT00199264
- Testing
- Albaconazole oral solution
- Volunteers
- 60 people
- Sponsor
- J. Uriach and Company
Candidiasis, Oral, HIV Infections
A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes
To determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the prophylaxis of oral candidiasis in patients with AIDS or AIDS related syndromes (group III or IV, CDC classification)
- Trial name
- NCT00002293
- Testing
- Nystatin
- Where
- 2 sites in United States
- Sponsor
- Bristol-Myers Squibb
Candidiasis, Oral, Thrush
Novel Rinse to Treat in Oral Candidiasis in Cancer Patients
The purpose of the study is to evaluate the efficacy of Iocide oral rinse as a treatment for Oral Candidiasis in any patient including but not limited to patients receiving radiation therapy or who have previously received…
- Conditions
- Candidiasis, Oral, Thrush, Candidiasis
- Trial name
- NCT00612963
- Testing
- Frio Oral Rinse
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Biomedical Development Corporation
Candidiasis
Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis
The purpose of this study is to further evaluate the safety and effectiveness of intravenous anidulafungin (Eraxis™) in patients with a diagnosis of candidemia or invasive candidiasis, which is a fungus infection of the blood or…
- Trial name
- NCT00496197
- Testing
- Eraxis (anidulafungin), Diflucan (fluconazole), Vfend (voriconazole)
- Where
- 43 sites in United States, South Korea
- Volunteers
- 282 people
- Sponsor
- Pfizer
Candidiasis, Invasive, Candidemia
Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)
This is a multicenter, open-label, non-comparator, single-arm study to evaluate the efficacy, safety, tolerability and PK (pharmacokinetics) of oral SCY-078 as an emergency use treatment for patients with a documented Candida…
- Trial name
- CARES (NCT03363841)
- Testing
- SCY-078
- Where
- 12 sites in United States, India and 2 more
- Volunteers
- 30 people
- Sponsor
- Scynexis, Inc.
Recurrent Vulvovaginal Candidiasis
A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute VVC in the past 12 months.
- Trial name
- VIOLET (NCT03562156)
- Testing
- Oteseconazole (VT-1161)
- Where
- 25 sites in United States
- Volunteers
- 438 people
- Sponsor
- Mycovia Pharmaceuticals Inc.
Candidiasis, Oral, HIV Infections
Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients
The purpose of this study is to compare the safety and effectiveness of 2 treatments for thrush (a fungal infection of the mouth and throat) in HIV-positive patients. Fluconazole is a drug that is commonly used to treat thrush.
- Trial name
- NCT00002446
- Testing
- Posaconazole, Fluconazole
- Where
- 18 sites in United States, Barbados
- Volunteers
- 300 people
- Sponsor
- Schering-Plough
Candidiasis, Oral, HIV Infections
An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects.
To assess the efficacy and safety of itraconazole oral solution in HIV-seropositive patients with oropharyngeal candidiasis that is refractory to fluconazole.
- Trial name
- NCT00002133
- Testing
- Itraconazole
- Where
- 18 sites in United States
- Sponsor
- Janssen, LP
Candida Vulvovaginitis
Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
This is a multicenter, randomized, double-blind, double-dummy, active-controlled, dose-finding study to compare the efficacy, safety and tolerability of oral SCY-078 versus oral fluconazole in adult female subjects 18 years and…
- Trial name
- DOVE (NCT03253094)
- Testing
- Fluconazole, SCY-078
- Where
- 25 sites in United States
- Volunteers
- 186 people
- Sponsor
- Scynexis, Inc.
Recurrent Vulvovaginal Candidiasis
A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC)
This is a prospective, randomized, multi-center, active-controlled, double-blind, double-dummy, multicenter, non-inferiority study comparing the clinical efficacy, safety and tolerability of ProF-001 to fluconazole.
- Trial name
- NCT04734405
- Testing
- Prof-001, Fluconazole 150 mg
- Where
- 29 sites in Austria, Poland and 1 more
- Volunteers
- 432 people
- Sponsor
- ProFem GmbH
Candida Vulvovaginitis
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis
This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in female subjects 12 years and older with AVVC.
- Trial name
- Vanish 306 (NCT03987620)
- Testing
- Ibrexafungerp
- Where
- 41 sites in United States, Bulgaria
- Volunteers
- 455 people
- Sponsor
- Scynexis, Inc.
Candidiasis, Esophageal, HIV Infections
A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems
To compare the safety, tolerance, and effectiveness of fluconazole and ketoconazole in the treatment of candidal esophagitis in immunocompromised patients.
- Trial name
- NCT00002304
- Testing
- Ketoconazole, Fluconazole
- Where
- 42 sites in United States, Canada
- Sponsor
- Pfizer